MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
July 25, 2023 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readoutsRandomization target of 200 patients...
Psoriatic Arthritis Therapeutics Market to Grow at a CAGR of 8.0% from 2022 to 2031, reaching USD 24.2 Billion: As per TMR Study
June 23, 2023 16:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 24, 2023 (GLOBE NEWSWIRE) -- The global psoriatic arthritis therapeutics market stood at USD 10.8 billion in 2021, and the global market is projected to...
Psoriatic Arthritis Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ Companies Working in the Domain
December 07, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Psoriatic Arthritis Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ Companies Working in the Domain The...
With 9.5% CAGR, Psoriatic Arthritis Treatment Market Size Hit USD 13.12 Billion in 2027
November 23, 2022 05:55 ET
|
Fortune Business Insights
Pune, India, Nov. 23, 2022 (GLOBE NEWSWIRE) -- The global psoriatic arthritis treatment market size is anticipated to touch USD 13.12 billion by the end of 2027 on account of the increasing...
Global Psoriasis Therapeutics Market to Reach $55.8 Billion by 2031: Says AMR
October 23, 2022 03:30 ET
|
Allied Market Research
Portland, OR, Oct. 23, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Psoriasis Therapeutics Market was estimated at $22.9 billion in 2021 and is...
Biosimilars in Immunology Prescriber Opinions Survey 2021 - Factors Influencing Choice of Prescribed Biosimilar Brands
January 20, 2022 05:58 ET
|
Research and Markets
Dublin, Jan. 20, 2022 (GLOBE NEWSWIRE) -- The "Prescriber Opinions on Biosimilars in Immunology" report has been added to ResearchAndMarkets.com's offering. This report covers the 7MM (United...
Psoriatic Arthritis Treatment Global Market Report 2020-2030: COVID-19 Growth and Changes
December 22, 2020 05:53 ET
|
Research and Markets
Dublin, Dec. 22, 2020 (GLOBE NEWSWIRE) -- The "Psoriatic Arthritis Treatment Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. ...
Psoriatic Arthritis Treatment Market to Exhibit 9.5% CAGR and Reach $13.12 Billion: Advanced Predictive Analytics offered by RCM to Boost Growth
September 09, 2020 06:18 ET
|
Fortune Business Insights
Pune, Sept. 09, 2020 (GLOBE NEWSWIRE) -- The global psoriatic arthritis treatment market size is anticipated to touch USD 13.12 billion by the end of 2027 on account of the increasing prevalence of...
National Rheumatology and Psoriasis Organizations Release Joint Guideline for Treating Psoriatic Arthritis
December 03, 2018 17:04 ET
|
American College of Rheumatology
Atlanta, Dec. 03, 2018 (GLOBE NEWSWIRE) -- The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) have released a joint treatment guideline for psoriatic arthritis (PsA)...
American College of Rheumatology Encourages Safe Adoption of Biosimilars During FDA Public Hearing on CT-P13, a Proposed Biosimilar for Infliximab (Remicade)
February 10, 2016 14:43 ET
|
American College of Rheumatology
ATLANTA, Feb. 10, 2016 (GLOBE NEWSWIRE) -- During a public meeting held Tuesday by the Food and Drug Administration (FDA)'s Arthritis Advisory Committee to review the license application of CT-P13,...